NSRX
Nasus Pharma Ltd. AMEX Listed Aug 13, 2025$3.39
Mkt Cap $29.2M
52w Low $1.98
17.6% of range
52w High $9.99
50d MA $3.19
200d MA $6.11
P/E (TTM)
-16.2x
EV/EBITDA
0.0x
P/B
—
Debt/Equity
0.0x
ROE
-211.6%
P/FCF
0.0x
RSI (14)
—
ATR (14)
—
Beta
5.02
50d MA
$3.19
200d MA
$6.11
Avg Volume
193.0K
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Yigal Alon 65 · Tel Aviv, L3 6744317 · IL
Data updated apr 26, 2026 3:51pm
· Source: massive.com